Febuxostat-d9 – 1 mg

Brand:
Cayman
CAS:
1246819-50-0
Storage:
-20
UN-No:
Non-Hazardous - /

Febuxostat-d9 is intended for use as an internal standard for the quantification of febuxostat (Item No. 14127) by GC- or LC-MS. Febuxostat is an antihyperuricemic nonpurine inhibitor of both the oxidized and reduced forms of xanthine oxidase.{22476} It inhibits bovine milk xanthine oxidase as well as mouse and rat liver xanthine oxidase/xanthine dehydrogenase (IC50s = 1.4, 1.8, and 2.2 nM, respectively).{42215} It is 10-30 times more potent than the hypoxanthine analog allopurinol (Item No. 10012597; Kis = 0.7 nM and 0.7 μM, respectively).{22474,22475} It decreases the serum level of urate in a potassium oxonate rat model of hyperuricemia (ED50 = 1.5 mg/kg).{42215} Febuxostat (0.75 mg/kg) also increases CNS expression of glutamate oxaloacetate transaminase 2 (GOT2) and improves neurological symptoms in a mouse model of secondary progressive experimental autoimmune encephalomyelitis (EAE).{42216} Formulations containing febuxostat have been used in the treatment of symptomatic hyperuricemia in patients with gout.  

 

Available on backorder

SKU: 25033 - 1 mg Category:

Description

An internal standard for the quantification of febuxostat by GC- or LC-MS


Formal name: 2-[3-cyano-4-[2-(methyl-d3)propoxy-1,1,2,3,3,3-d6]phenyl]-4-methyl-5-thiazolecarboxylic acid

Synonyms: 

Molecular weight: 325.4

CAS: 1246819-50-0

Purity: ≥99% deuterated forms (d1-d9)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Small Molecule Inhibitors|MMPs||Product Type|Biochemicals|Small Molecule Inhibitors|Nucleic Acid Turnover/Signaling||Research Area|Neuroscience